Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients

Clinical Drug Investigation

Volumn 27, Issue 4, 2007, Pages 251-258

  Miura, Masatomo ^a   Inoue, Kazuyuki ^a   Satoh, Shigeru ^b   Itoh, Yoshihiko ^c   Kagaya, Hideaki ^a   Tada, Hitoshi ^a   Tanaka, Yorihisa ^c   Habuchi, Tomonori ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; LANSOPRAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; TACROLIMUS;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME IMMUNOASSAY; ENZYME POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIXED FUNCTION OXYGENASES; MYCOPHENOLIC ACID; POLYMORPHISM, GENETIC; STEREOISOMERISM; TACROLIMUS;

EID: 33947307609     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727040-00004     Document Type: Article

References (33)

1. Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1990; 252: 1289-95
2. Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-16
3. Katsuki H, Nakamura C, Arimori K, et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997; 52: 391-6
4. Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47: 410-8
5. Miura M, Tada H, Yasui-Furukori N, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5- hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 2004; 60: 623-8
6. Kim K, Shon J, Park J, et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 2002; 72: 90-9
7. Kim KA, Kim MJ, Park JY, et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 2003; 31: 1227-34
8. Katsuki H, Hamada A, Nakamura C, et al. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 2001; 57: 709-15
9. Miura M, Kagaya H, Tada H, et al. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica 2005; 35: 479-86
10. Desta Z, Zhao X, Shin J-G, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
11. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66
12. Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16: 837-46
13. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-24
14. Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37: 1730-2
15. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-7
16. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54
17. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in Whites and South Asians. Transplantation 2005; 79: 499-502
18. Saito M, Yasui-Furukori N, Uno T, et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 2005; 59: 302-9
19. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
20. Tateishi T, Watanabe M, Moriya H, et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57: 935-9
21. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 82-91
22. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91
23. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-72
24. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-91
25. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9
26. Itoh K, Inoue K, Yanagiwara S, et al. Rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Bio Pharm Bull 1999; 22: 7-9
27. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002; 12: 331-4
28. Miura M, Tada H, Suzuki T. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 804: 389-95
29. Kagaya H, Inoue K, Miura M, et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi 2006; 126: 1357-62
30. Miura M, Tada H, Yasui-Furukori N, et al. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 2005; 60: 61-8
31. Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 2006; 126: 395-402
32. Troppmann C, Papalois BE, Chiou A, et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. J Am Coll Surg 1995; 180: 433-43
33. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409-14